Video: BioNTech's Marett On Sanofi Deal And Immunotherapy

 
• By Lucie Ellis-Taitt
  
Generate a summary of this article
Listen to this article
Beta

In this video interview BioNTech chief operating officer, Sean Marett, discusses his company's recent Sanofi immunotherapy deal with Mike Ward, global director of content for Informa Pharma Insights, at BIO-Europe in Munich, Germany. They chat about BioNTech's messenger RNA technology, co-development plans with Sanofi and the potential for immunotherapy combination studies.

In this video interview BioNTech chief operating officer, Sean Marett, discusses his company's recent Sanofi immunotherapy deal with Mike Ward, global director of content for Informa Pharma Insights, at BIO-Europe in Munich, Germany. They chat about BioNTech's messenger RNA technology, co-development plans with Sanofi and the potential for immunotherapy combination studies.

Look out for more BIO-Europe exclusive interviews all this week on Scrip. To see more video interviews and panel discussions...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.